SLC6A4 and major depressive disorder: As illustrated in Figure 1, glutamatergic signaling interfaces with neuroimmune function in glial cells, and serotonergic dysfunction in MDD (e.g., altered SERT function) could lead to dysregulated glutamatergic signaling and, subsequently, altered neuroimmune function.